Posted in | News | Nanobusiness

AION Diagnostics Announces Theodor Dingermann to Advisory Board

AION Diagnostics Inc, a nano-diagnostics company commercializing medical imaging agents, has announced the appointment of Theodor Dingermann, Ph.D. to its Scientific Advisory Board.

Professor Dingermann has over 30 years experience in the German pharmaceutical industry. He is the biotechnology advisor to the State of Hesse as well as Editor-in-chief of two leading German pharmaceutical journals; 'DIE PHARMAZIE' and 'Pharmazie in unserer Zeit.'

'We very much look forward to the expertise in molecular biology and biochemistry Prof. Dingermann will bring to AION, particularly to our Molecular Imaging platform,' said AION President and CEO, Dr. Anna Kluczewska.

Since 1990, Prof. Dingermann has been Full Professor of Pharmaceutical Biology at Goethe University in Frankfurt, Germany. He is Chairman of the working group of biopharmaceuticals and Vice-Chairman on pharmaceutical biology of the German Pharmacopeia Commission. From 2000 to 2004 he was President of the German Pharmaceutical Society. Prof. Dingermann studied Pharmacy at the University of Erlangen, Germany. On obtaining his Ph.D. in Biochemistry, he worked as a Post-Doctoral Research Fellow at Yale University, New Haven.

The AION Scientific Advisory Board is chartered to contribute independent scientific and strategic advice to the Company's operations.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.